Scholarlink

Background <p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder associated with impaired barrier function, pruritus, and reduced quality of life. Conventional topical corticosteroid therapy is often limited by poor skin penetration, rapid drug release, and local adverse effects. Therefore, there is a need for advanced nanocarrier-based systems to improve dermal delivery and therapeutic efficiency.</p> Methods <p>Halobetasol propionate (HP)-loaded cubosomes were developed using a top-down approach with glyceryl monooleate (GMO) as the lipid phase and Poloxamer 407 as the stabilizer. A total of thirteen formulations (C1–C13) were prepared and optimized based on particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The optimized cubosomal dispersion was incorporated into a Carbopol 940 gel and evaluated for physicochemical properties, in vitro drug release, and short-term stability.</p> Results <p>The optimized formulation (C1) exhibited a particle size of 135.70 ± 0.58&#xa0;nm, PDI of 0.249 ± 0.01, zeta potential of − 21.50 ± 4.25 mV, and high entrapment efficiency (91.95 ± 0.50%). The cubosomal gel showed suitable pH (6.2), high viscosity, and good spreadability for topical application. In vitro drug release studies demonstrated sustained release behavior with 87.20% drug release over 24&#xa0;h, following diffusion-controlled kinetics. Stability studies indicated minimal variation in drug release over 30 days, confirming formulation stability.</p> Conclusion <p>The developed HP-loaded cubosomal gel provides controlled and sustained drug delivery with favorable physicochemical properties and stability. This system represents a promising topical therapeutic strategy for improved management of atopic dermatitis.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cubosomal Gel-Based Delivery of Halobetasol Propionate: A Novel Topical Strategy for Sustained Management of Atopic Dermatitis

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Sonam M Gandhi,
  • Kaushal R Ladumor,
  • Shadma Wahab,
  • Saad Ali Alshehri,
  • Upama N Trivedi,
  • Devesh U Kapoor

摘要

Background

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder associated with impaired barrier function, pruritus, and reduced quality of life. Conventional topical corticosteroid therapy is often limited by poor skin penetration, rapid drug release, and local adverse effects. Therefore, there is a need for advanced nanocarrier-based systems to improve dermal delivery and therapeutic efficiency.

Methods

Halobetasol propionate (HP)-loaded cubosomes were developed using a top-down approach with glyceryl monooleate (GMO) as the lipid phase and Poloxamer 407 as the stabilizer. A total of thirteen formulations (C1–C13) were prepared and optimized based on particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The optimized cubosomal dispersion was incorporated into a Carbopol 940 gel and evaluated for physicochemical properties, in vitro drug release, and short-term stability.

Results

The optimized formulation (C1) exhibited a particle size of 135.70 ± 0.58 nm, PDI of 0.249 ± 0.01, zeta potential of − 21.50 ± 4.25 mV, and high entrapment efficiency (91.95 ± 0.50%). The cubosomal gel showed suitable pH (6.2), high viscosity, and good spreadability for topical application. In vitro drug release studies demonstrated sustained release behavior with 87.20% drug release over 24 h, following diffusion-controlled kinetics. Stability studies indicated minimal variation in drug release over 30 days, confirming formulation stability.

Conclusion

The developed HP-loaded cubosomal gel provides controlled and sustained drug delivery with favorable physicochemical properties and stability. This system represents a promising topical therapeutic strategy for improved management of atopic dermatitis.

Graphical Abstract